April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
BDNF Mediated Functional and Structural Optic Nerve Protection in Canine Hypertensive Eyes
Author Affiliations & Notes
  • S. D. Grozdanic
    Veterinary Clinical Sciences, Iowa State University, Ames, Iowa
  • H. Kecova
    Veterinary Clinical Sciences, Iowa State University, Ames, Iowa
  • M. M. Harper
    Veterinary Clinical Sciences, Iowa State University, Ames, Iowa
  • M. H. Kuehn
    Ophthal & Visual Sciences,
    University of Iowa, Iowa City, Iowa
  • E. B. Lavik
    Engineering, Case Western Reserve University, Cleveland, Ohio
  • R. H. Kardon
    Ophthalmology and Visual Sciences,
    University of Iowa, Iowa City, Iowa
  • Footnotes
    Commercial Relationships  S.D. Grozdanic, None; H. Kecova, None; M.M. Harper, None; M.H. Kuehn, None; E.B. Lavik, None; R.H. Kardon, None.
  • Footnotes
    Support  Department of Veterans Affairs - Rehabilitation Research and Development Service Grant C3919R and Iowa City VA Center for Prevention and Treatment of Vision Loss
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2522. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. D. Grozdanic, H. Kecova, M. M. Harper, M. H. Kuehn, E. B. Lavik, R. H. Kardon; BDNF Mediated Functional and Structural Optic Nerve Protection in Canine Hypertensive Eyes. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2522.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate therapeutic effects of chronic brain derived neurotrophic growth factor (BDNF) administration in a canine model of ocular hypertension.

Methods: : Intraocular pressure (IOP) was elevated for 60 minutes to the level of systolic blood pressure using an anterior chamber canula connected to a saline reservoir. Two hours after induction of ocular hypertension intravitreal injections of sustained release BDNF-PLGA microspheres (with degradation and release kinetics of 2 months) or blank PLGA microspheres were given. The function of the optic nerve was evaluated using pattern electroretinography (pERG). Thickness of the retinal nerve fiber layer (RNFL) was evaluated using optical coherence tomography (OCT).

Results: : Four weeks after induction of ocular hypertension, BDNF-PLGA injected eyes had significantly better pERG amplitudes (5.3+0.5 µV; mean+SEM, p=0.0047, ANOVA) when compared to dogs which did not receive any treatment (2.5+0.6 µV; mean+SEM) or received only blank microsphere injection (2.4+0.6 µV; mean+SEM). PERG amplitude for healthy non-operated dogs was 6.2+0.5 µV. OCT analysis in BDNF injected eyes showed significant preservation of the inferior RNFL (97.2+3.4 µm; p=0.005) when compared to hypertensive eyes which did not receive any treatment (80.7+4.9 µm) or received blank microspeheres (81.1+2.1 µm). Inferior RNFL thickness in healthy dogs was 98+2.9 µm. Six months post injection pERG function significantly decreased in BDNF treated eyes and was not significantly different compared to hypertensive non-treated eyes.

Conclusions: : Chronic delivery of BDNF for 2 months had a significant protective effect on optic nerve function and structure. However, optic nerve degeneration continued to progress once when BDNF trophic support ceased. Chronic BDNF delivery may be an effective strategy for protection of optic nerve function and structure from ocular hypertension.

Keywords: neuroprotection • growth factors/growth factor receptors • ganglion cells 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×